This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arnould, L. Articles by Coudert, B. P. Search for Related Content PubMed PubMed Citation Articles by Arnould, L. Articles by Coudert, B. P.

Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification

Authors' Affiliations: ¹ CLCC G-F Leclerc and 1FR100, Dijon, France; ² CLCC Institut Curie; ³ Hôpital Tenon, Paris, France; ⁴ CLCC A Lacassagne, Nice, France; ⁵ Hopital Laënnec, Nantes, France; ⁶ CLCC Jean Perrin, Clermont-Ferrand, France; and ⁷ Laboratoire Roche-Pharma, Neuilly sur Seine, France

Requests for reprints: Laurent Arnould, Department of Pathology, Centre G-F Leclerc, 1 Rue Pr Marion, 21000 Dijon Cedex, France. Phone: 33-380-737-723; Fax: 33-380-737-717; E-mail: larnould{at}dijon.fnclcc.fr.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Purpose: Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) are used to determine human epidermal growth factor receptor-2 (HER-2) status and patient eligibility for trastuzumab therapy. Using FISH and IHC, we analyzed the relationship between pathologic complete response to trastuzumab-based neoadjuvant therapy and level of HER-2 amplification in locally advanced breast cancer.

Experimental Design: Breast biopsies from 93 HER-2–positive patients treated with trastuzumab-based neoadjuvant therapy were centrally collected and analyzed retrospectively for HER-2 amplification using FISH and HER-2 overexpression using IHC. Tumors were classified by FISH as no, low, or high amplification. Biopsies were reassessed centrally by IHC and graded 0, 1+, 2+, or 3+.

Results: HER-2 status of tumor samples as assessed by FISH and IHC correlated: 16 no amplification (11 IHC 1+ and 5 IHC 2+), 27 low amplification (26 IHC 3+ and 1 IHC 2+), and 50 high amplification (all IHC 3+). Trastuzumab-based neoadjuvant therapy achieved pathologic complete response in 35 of 93 (37.6%) tumors. Pathologic complete response rate in low- and high-amplification tumors was significantly higher than in no-amplification tumors (44% versus 6%; P < 0.004). Pathologic complete response rate in high-amplification tumors was significantly higher compared with low-amplification tumors (56% versus 22%; P < 0.005). In the subgroup of low- plus high-amplification tumors, no correlation was found between pathologic complete response rate and IHC score, treatment regimen, T or N stage, tumor grade, or hormonal receptors.

Conclusions: This is the first study to show positive correlation between level of HER-2 amplification assessed by FISH and rate of pathologic complete response to trastuzumab-based neoadjuvant treatment.

In the neoadjuvant setting, primary systemic therapy with trastuzumab-based combination chemotherapy has also shown clinical benefit in terms of both overall response and pathologic complete response rates (9–13). The goals of primary systemic therapy are to treat occult systemic disease and decrease tumor size, thus allowing for breast-conserving surgery (14). Primary systemic therapy with trastuzumab may prove particularly beneficial for women with HER-2–positive locally advanced breast cancer and, as such, accurate and efficient HER-2 status testing should be done at the earliest opportunity after diagnosis (10, 15, 16).

Currently, both immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are the established HER-2 testing methods. IHC detects the amount of HER-2 protein expressed on the surface of cells and relies on a qualitative scoring system from 0 to 3+, with 0 to 1+ being negative for HER-2 overexpression, 2+ being borderline, and 3+ indicating positive HER-2 status. FISH detects amplification of the HER-2 gene and thus tumors are interpreted as HER-2 negative or positive by counting the number of HER-2 gene copies. IHC is relatively simple and cost effective; however, results are reliant on several variables and can be associated with interpretation errors (17–19). In the North American clinical trials of adjuvant trastuzumab, a moderately high level of false-positive HER-2 status cases were initially reported in patients tested locally with IHC (20, 21). However, if IHC procedures are standardized and calibrated with FISH, a high degree of concordance between IHC and FISH exists (22, 23). Other studies have also reported relatively good concordance between IHC 3+ and FISH-positive as well as IHC 0/1+ and FISH-negative scores but differences between the two assays for cases surrounding the IHC 2+ score (18, 24, 25). The best way to assess HER-2 status for trastuzumab therapy is still in debate (26).

Trastuzumab-based neoadjuvant studies that enrolled both IHC 2+ and 3+ patients showed that patients who scored IHC 3+ were more responsive to trastuzumab treatment than those who scored IHC 2+ (11, 27). In clinical practice, most IHC 2+ scores are followed by additional FISH testing to determine HER-2 status accurately. As pathologic complete response is often predictive of postsurgical disease-free survival and overall survival, we sought to ascertain whether a relationship between level of HER-2 amplification, as assessed by FISH, and pathologic complete response existed in women diagnosed with HER-2–positive locally advanced breast cancer who were treated preoperatively with a combination of trastuzumab plus chemotherapy.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Patients. Breast biopsies from 93 patients who had received trastuzumab in combination with chemotherapy as primary systemic therapy for operable, HER-2–positive, stage II/III breast cancer were collected from 19 centers in France. All patients provided written, informed consent for their tissue material and clinical data to be centrally collected and used for research purposes.

Patients were aged 27 to 67 years and had unilateral, histologically confirmed, T₂ or T₃, N_0-1, nonmetastatic, noninflammatory, HER-2–positive breast cancer requiring mastectomy. Most patients were treated preoperatively in two open-label, phase II clinical trials: TAXHER01 (n = 21) and GETNA01 (n = 61; refs. 11, 13). An additional 11 patients who had been treated with the same preoperative regimen as in the TAXHER01 trial were also included in the analyses.

All patients had received weekly neoadjuvant trastuzumab (4 mg/kg loading dose followed by 2 mg/kg once weekly) in combination with either docetaxel (100 mg/m² every 3 weeks for six cycles; n = 32) or docetaxel (75 mg/m² every 3 weeks for six cycles) plus carboplatin (area under the curve of 6 every 3 weeks for six cycles; n = 61). Three weeks after the last course of trastuzumab-based neoadjuvant treatment, pathologic complete response was assessed according to Chevallier's classification (28); no carcinoma evidence either in the breast or in the lymph nodes, with or without in situ carcinoma, was considered as pathologic complete response.

HER-2 testing. All patients had initially tested IHC 3+ for HER-2 status, as determined by local participating centers. For this study, HER-2 status was analyzed retrospectively and centrally assessed using both IHC and FISH.

Central IHC analyses for HER-2 overexpression were done with A485 polyclonal antibody (dilution 1:1,800) on the BenchMark XT system (Ventana Medical Systems, Inc.). Biopsies were graded according to the HercepTest (DAKO) scoring system (0, 1+, 2+, or 3+). FISH analyses were done using the HER-2 Probe (Oncor) and BenchMark XT system. The pathologist who did FISH analyses was blinded to all other patient data, including the original and central IHC test results. For each tumor, the mean of HER-2 signals was calculated by counting signals in 60 tumor cell nuclei. The degree of HER-2 amplification in tumors, as assessed by single-color FISH, was classified as follows: no amplification (mean, <6 signals/nuclei); low amplification (mean, 6-10 signals per nuclei); or high amplification (mean, >10 signals/nuclei or uncountable due to clusters of signals). Several studies have proposed the cutoff value of six copies between no amplification and amplification as appropriate for single-color FISH (29–31) and this is the cutoff recommended by the American Society of Cinical Oncology/College of American Pathologists (32). The cutoff of 10 gene copies number per nuclei between low and high amplification is somewhere arbitrary but it was chosen because it is the same are those proposed with chromogenic in situ hybridization (33–35). It was also chosen because over this cutoff, due to clusters and small aggregates, signals are almost always not possible to be precisely counted.

Borderline tumors (mean approaching six signals per nuclei) were analyzed by double-color FISH using a HER-2 gene–specific probe and a centromeric probe for chromosome 17 (PathVysion HER-2 DNA Probe kit, Vysis-Abbott) to determine HER-2 amplification. In these cases, HER-2 amplification was defined by a ratio of HER-2 over chromosome 17 centromeric signals of 2.2 (32).

The scores obtained by FISH for each tumor were subsequently compared with multiple patient and tumor variables (including treatment regimen, patient age, tumor-node-metastasis staging, and IHC score) and pathologic complete response rates to determine if FISH testing could predict more accurately patient response to neoadjuvant treatment with trastuzumab plus chemotherapy. The subpopulation of patients eligible for trastuzumab treatment (IHC 3+ and/or FISH positive) was also analyzed for variables predictive of pathologic complete response.

Statistics. All analyses were done with Stata software. Univariate analyses were done using Pearson's ² or Fisher's exact test with a bilateral 5% type I error. Initial analyses involved the whole studied population. Analyses were then done on the subpopulation of patients eligible for trastuzumab treatment [central IHC 3+ (n = 76) and central IHC 2+ with FISH amplification (n = 1)] to study the prognostic factors of pathologic complete response. Logistic regression analysis was used to estimate odds ratios and two-sided 95% confidence intervals. In the model of logistic regression, we included variables with a P < 0.05 in the univariate analysis; treatment and Scarff-Bloom-Richardson grade were also included because of their clinical relevance.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Patients. Baseline patient demographics are summarized in Table 1 . All patients had invasive breast cancer, with most patients having T₂, N_0-1, and grade 2/3 disease. No patients showed evidence of metastatic disease. Mean age was 46 years (range, 27-67 years). According to Chevalier's classification, 35 of 93 (37.6%) patients had a pathologic complete response, whereas 57 of 93 (61.3%) patients experienced pathologic partial or no response.

Sixteen (17.2%) tumors were categorized as no amplification, with 11 (69%) rated 1+ on central IHC review and 5 (31%) rated 2+. Mean signals per tumor nuclei was 2.6 (range, 1.1-5.2) for the 16 tumors in this category. The absence of amplification for the tumor with the highest mean (5.2) was confirmed by double-color FISH, with the ratio HER-2/chromosome 17 being <1.8.

Analysis of tumor characteristics according to FISH results. There were no significant differences between the three groups of FISH amplification (no amplification, low amplification, and high amplification) in terms of treatment given, age, or T or N stage (Table 2 ). As expected, amplification of the HER-2 gene as assessed by FISH correlated with tumor grade, with significantly more grade 3 tumors displaying high HER-2 amplification [28 of 49 (56%); P = 0.021]. High amplification of HER-2 also correlated with hormone receptor status: a significant number of hormone receptor–negative tumors [27 of 36 (75%)] were classified as high amplification and no hormone receptor–negative tumors were classified as no amplification (P = 0.001).

Analysis of variables that can predict pathologic complete response. Tumor characteristics according to pathologic complete response are summarized in Table 3 . There was no relationship between pathologic complete response and treatment regimen, patient age, T or N stage, or Scarff-Bloom-Richardson grade. Pathologic complete response was significantly more frequent in FISH-amplified tumors (44%) than in nonamplified tumors (6%; P = 0.004). As expected, pathologic complete response also occurred significantly more frequently in HER-2 3+ tumors (P = 0.009). There was also a trend toward pathologic complete response in hormone receptor–negative tumors (P = 0.051).

	Discussion

Top Abstract Materials and Methods Results Discussion References

Several phase II studies of trastuzumab plus chemotherapy as primary systemic therapy have shown substantially improved response rates in this population of patients at high risk for relapse, with most overall response rates 75% (for detailed review, see ref. 13). However, pathologic complete response rates, which are often considered more indicative of disease-free and overall survival, have been more variable, ranging from 7% in one small scale study (n = 14) of trastuzumab plus docetaxel and epirubicin to >40% in several larger studies (for detailed review, see ref. 13). Thus, any baseline factor that could be used to help in predicting which patients would benefit most from trastuzumab-based neoadjuvant regimens would be invaluable to clinicians.

In our study, the only variable related to pathologic complete response in the subpopulation of patients eligible for treatment with trastuzumab (IHC 2+/3+ and/or FISH positive) was the level of HER-2 amplification as assessed by FISH. Two neoadjuvant studies of trastuzumab plus a taxane, which enrolled both IHC 2+ and 3+ patients, have shown that patients who scored IHC 3+ were more likely to respond to trastuzumab treatment than those patients who scored IHC 2+ for HER-2 overexpression (13, 27). Although all FISH-positive tumors were centrally confirmed as IHC 2+ or 3+ in this study, our classification of HER-2 amplification by FISH was more precise in identifying those patients who would have benefited most from trastuzumab. Indeed, pathologic complete response was seen significantly more frequently in high-amplification FISH tumors compared with low-amplification tumors in patients who were eligible to receive trastuzumab treatment. This degree of subclassification with regard to HER-2 status would not have been possible using IHC. Therefore, FISH may be a more accurate HER-2 testing method to predict pathologic complete response in the neoadjuvant setting.

Interestingly, our results are in line with retrospective analyses done on patients enrolled in the pivotal trials of trastuzumab in HER-2–positive metastatic breast cancer. Whereas patients with IHC scores of 2+ and 3+ were initially eligible for the phase III trials, subset analysis by Slamon et al. (4) revealed that the clinical benefits of trastuzumab plus paclitaxel were greatest in patients whose tumors were graded IHC 3+. Furthermore, retrospective analyses revealed that patients who tested HER-2 positive by FISH experienced significantly better response rates and improved survival with trastuzumab than those patients whose tumors were FISH negative. This suggests that FISH may predict more accurately which patients will obtain the most clinical benefit from trastuzumab therapy in the metastatic setting (36).

Although the number of cases included in this study is not large and despite the size of the confidence intervals, our analysis shows statistically significant differences between the two groups of amplification in term of pCR. These results have certainly to be confirmed in the future in a larger series. Moreover, our results are in concordance with those published recently by Giuliani et al. (37) in metastatic HER-2–positive breast cancer treated with trastuzumab alone or combined with chemotherapy (mainly paclitaxel). In the group of patient treated with trastuzumab and chemotherapy, they have shown a significantly positive correlation between level of HER-2 gene amplification and the clinical objective response.

Nevertheless, in a recent neoadjuvant study by Hurley et al. (38) evaluating trastuzumab plus docetaxel and cisplatin as primary systemic therapy for patients with HER-2–positive (IHC 2+/3+ or FISH positive) locally advanced breast cancer, no significant difference in pathologic complete response rates according to FISH status (FISH positive versus FISH negative) was found. Unexpectedly, FISH status also did not affect rates of either progression-free or overall survival in this study. Although our results seem to contradict this study, the population analyzed may be different. Indeed, IHC testing, used for the patient screening, seemed very sensitive in the Hurley et al. study, as only 60% of IHC 3+ tumors were FISH positive, whereas reported rates in the literature are 90% (18, 24, 25, 39). Although our study did not evaluate survival, these differing results about the relationship between FISH positivity and pathologic complete response highlight the need to standardize both IHC and FISH procedures for determination of HER-2 gene status.

Currently, there is variability with respect to HER-2 testing in terms of a particular commercial kit, antibody, probe, or cutoff value, and discrepancies due to variability between kits may occur (40). In terms of cutoff values with FISH amplification, our results, which were obtained on clinicopathologic data, are in line with those obtained with biological data in a recently published study by Dal Lago et al. (29) and those proposed recently by the American Society of Clinical Oncology and the College of American Pathologists (32). In the Dal Lago et al. study, cutoff values of 4 and 6 copies for no amplification and amplification were evaluated with single-color FISH. Good correlation only existed between the cutoff value of 6 and their mRNA assay.

The results of our study also highlight that accurate HER-2 testing is essential for optimal patient management with trastuzumab. In the neoadjuvant setting, initial IHC screening (which would be negative for the majority for tumors) could be used, followed by FISH testing for IHC 2+ or 3+ tumors. This supplementary FISH testing would exclude false-positive tumors by confirming HER-2 amplification and precisely determine the level of HER-2 amplification. This need of accuracy was particularly emphasized in two large trials that have shown discordance between local and central HER-2 testing for IHC (20) or for IHC and FISH (41).

In conclusion, our study showed a significantly positive correlation between pathologic complete response rate and level of HER-2 amplification as assessed by FISH in stage II/III breast tumors. These findings may have clinical implications for the management of patients with HER-2–positive locally advanced breast cancer. The degree of amplification as assessed by FISH may be an additional source of information for physicians wishing to clarify individual risk-benefit assessments for critical patients considering preoperative treatment with trastuzumab-based chemotherapy. However, it remains unknown whether a relationship exists between pathologic complete response, HER-2 level of amplification as assessed by FISH, and postoperative survival rates in women with HER-2–positive locally advanced breast cancer who are treated preoperatively with trastuzumab-based regimens. Further studies on the effect of level of HER-2 amplification on the behavior of tumors treated with trastuzumab in both the metastatic and adjuvant breast cancer settings are also needed.

	Acknowledgments

 
We thank the Ligue de Cote d'Or Contre le Cancer, C. Harris, and D. James for assistance in manuscript preparation; Drs. J. Garnier and F. Campana (Roche Laboratories); Prof. N. Namer and P. Atalli (GETNA); and G. Milla (OSMO).

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Presented in part at the 29th San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006.

Received 12/20/06; revised 6/26/07; accepted 7/10/07.

	References

Top Abstract Materials and Methods Results Discussion References

 

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82.[Abstract/Free Full Text]
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–12.[Abstract/Free Full Text]
3. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265–74.[Abstract/Free Full Text]
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.[Abstract/Free Full Text]
5. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–20.[Abstract/Free Full Text]
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72.[Abstract/Free Full Text]
7. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–84.[Abstract/Free Full Text]
8. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin, and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study [abstract 1]. Breast Cancer Res Treat 2005;94 Suppl 1:S5.
9. Bines J, Murad A, Lago S, Ferrari B, Andrade J, Abdo E. Multicenter Brazilian study of weekly docetaxel and trastuzumab as primary therapy in stage III, HER-2 overexpressing breast cancer [abstract 268]. Proc Am Soc Clin Oncol 2003;22:242.
10. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676–85.[Abstract/Free Full Text]
11. Coudert BP, Arnould L, Moreau L, et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 2006;17:409–14.[Abstract/Free Full Text]
12. Van Pelt AE, Mohsin S, Elledge RM, et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 2003;4:348–53.[Medline]
13. Coudert BP, Largillier R, Arnould L, et al. Neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of a GETN(A) group and OSMO multicenter phase II trial (GETN[A]-1 trial). J Clin Oncol 2007;25:2678–84.[Abstract/Free Full Text]
14. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist 2006;11:574–89.[Abstract/Free Full Text]
15. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865–78.[Abstract/Free Full Text]
16. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569–83.[Abstract/Free Full Text]
17. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003;16:173–82.[CrossRef][Medline]
18. Diaz NM. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy. Cancer Control 2001;8:415–8.[Medline]
19. Van de Vijver M, Rueschoff J, Penault-Llorca F, Bilous M, Hanna W. Chromogenic in-situ hybridization (CISH) compared with FISH and IHC for detection of HER2 gene amplification: an international validation ring study. San Antonio (TX): 26th Annual San Antonio Breast Cancer Symposium; 2003.
20. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852–4.[Abstract/Free Full Text]
21. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855–7.[Abstract/Free Full Text]
22. Vincent-Salomon A, MacGrogan G, Couturier J, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 2003;42:337–47.[CrossRef][Medline]
23. Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Mathoulin-Pelissier S. Re: HER2 testing in the real world. J Natl Cancer Inst 2003;95:628–9.[Free Full Text]
24. Ellis CM, Dyson MJ, Stephenson TJ, Maltby EL. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol 2005;58:710–4.[Abstract/Free Full Text]
25. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374–81.[Abstract/Free Full Text]
26. Yaziji H, Gown AM. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? Hum Pathol 2004;35:143–6.[CrossRef][Medline]
27. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21:46–53.[Abstract/Free Full Text]
28. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223–8.[Medline]
29. Dal Lago L, Durbecq V, Desmedt C, et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 2006;5:2572–9.[Abstract/Free Full Text]
30. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004;10:4793–8.[Abstract/Free Full Text]
31. Vera-Roman JM, Rubio-Martinez LA. Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch Pathol Lab Med 2004;128:627–33.[Medline]
32. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118–45.[Abstract/Free Full Text]
33. Hanna WM, Kwok K. Chromogenic in situ hybridization: a viable alternative to fluorescence in situ hybridization in the HER2 testing algorithm. Mod Pathol 2006;19:481–7.[CrossRef][Medline]
34. Tanner M, Gancberg D, Di LA, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467–72.[Abstract/Free Full Text]
35. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase II in primary and metastatic breast cancer. Cancer Res 2001;61:5345–8.[Abstract/Free Full Text]
36. Cobleigh M, Vogel C, Tripathy D, Mass R, Murphy M, Press M. Fluorescence in situ hybridization (FISH) may accurately select patients likely to benefit from Herceptin monotherapy. Eur J Cancer 2001;37:S192.
37. Giuliani R, Durbecq V, Di LA, et al. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer 2007;43:725–35.[CrossRef][Medline]
38. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006;24:1831–8.[Abstract/Free Full Text]
39. Couturier J, Vincent-Salomon A, Nicolas A, et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 2000;13:1238–43.[CrossRef][Medline]
40. Ellis IO, Bartlett J, Dowsett M, et al. Best practice no. 176: updated recommendations for HER2 testing in the UK. J Clin Pathol 2004;57:233–7.[Abstract/Free Full Text]
41. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:3032–8.[Abstract/Free Full Text]

This article has been cited by other articles:

				M. Brunelli, E. Manfrin, G. Martignoni, K. Miller, A. Remo, D. Reghellin, S. Bersani, S. Gobbo, A. Eccher, M. Chilosi, et al. Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification: Evaluation According to ASCO/CAP Criteria Am J Clin Pathol, May 1, 2009; 131(5): 678 - 682. [Abstract] [Full Text] [PDF]

				J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine Oncologist, April 1, 2009; 14(4): 320 - 368. [Abstract] [Full Text] [PDF]

				M. Kakarala and M. S. Wicha Implications of the Cancer Stem-Cell Hypothesis for Breast Cancer Prevention and Therapy J. Clin. Oncol., June 10, 2008; 26(17): 2813 - 2820. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arnould, L. Articles by Coudert, B. P. Search for Related Content PubMed PubMed Citation Articles by Arnould, L. Articles by Coudert, B. P.